Drugs / Dexamethasone Oral
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06126354 Background | Jul 2024 → Nov 2025 | NAFLD1, prediabetes syndrome | Columbia University | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexamethasone Oral | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126354 ↗ |
| Modality | Small molecule | “Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.” NCT06126354 ↗ |
| Route | Oral | “administered orally” NCT06126354 ↗ |